Cargando…
Bendamustine/obinutuzumab/remdesivir: Absence of CD19-B lymphocytes, decrease in CD4-T lymphocytes and lack of efficacy: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325903/ http://dx.doi.org/10.1007/s40278-021-99786-2 |
Ejemplares similares
-
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020) -
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma
por: Grigg, Andrew, et al.
Publicado: (2017) -
Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma
por: Younes, Anas, et al.
Publicado: (2022) -
Bendamustine/obinutuzumab: COVID-19 disease, pancytopenia and hypogammaglobulinaemia: case report
Publicado: (2021) -
Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)